VA therapy after stem cell transplant for MDS or AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called VA as a maintenance treatment to prevent relapse after a stem cell transplant for people with MDS (myelodysplastic syndromes) or AML (acute myeloid leukemia). It may help keep the cancer away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have MDS or AML and have had a stem cell transplant (allogeneic)
- Your blood counts and bone marrow must show you are in complete remission (cancer is not active)
- You must not have active infections or unstable health issues
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests whether adding venetoclax (a pill) to a lower-intensity bone marrow or stem cell transplant, and continuing it after transplant, helps prevent acute myeloid leukemia (AML) from coming back. You may join if you are in first remission and have a suitable donor.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.